兔抗APOBEC3D/F多克隆抗體

Background:

DNA deaminase (cytidine deaminase) which acts as an inhibitor of retrovirus replication and retrotransposon mobility via deaminase-dependent and -independent mechanisms. Exhibits antiviral activity against vif-deficient HIV-1. After the penetration of retroviral nucleocapsids into target cells of infection and the initiation of reverse transcription, it can induce the conversion of cytosine to uracil in the minus-sense single-strand viral DNA, leading to G-to-A hypermutations in the subsequent plus-strand viral DNA. The resultant detrimental levels of mutations in the proviral genome, along with a deamination-independent mechanism that works prior to the proviral integration, together exert efficient antiretroviral effects in infected target cells. Selectively targets single-stranded DNA and does not deaminate double-stranded DNA or single-or double-stranded RNA. May inhibit the mobility of LTR and non-LTR retrotransposons.

Applications:

WB, IHC

Name of antibody:

APOBEC3D/F

Immunogen:

Synthesized peptide derived from internal of human APOBEC3D/F.

Full name:

apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3D/F

Synonyms：

A3D; ARP6; APOBEC3E; APOBEC3DE/A3F; KA6; ARP8; BK150C2.4.MRNA

SwissProt:

Q96AK3/Q8IUX4

IHC positive control:

Human placenta tissue

IHC Recommend dilution:

50-100

WB Predicted band size:

47/45 kDa

WB Positive control:

MCF7 cells and COS-7cells lysates

WB Recommended dilution:

500-3000